Loading company…
MOLCURE Inc. uses AI-driven molecular design to support drug discovery for pharmaceutical and biotechnology companies.
Founded in 2013 and headquartered in Kanagawa, Japan, MOLCURE offers an AI-powered de novo discovery platform, high-throughput screening, next-generation sequencing and an AI-based lead optimization platform. Its founder and CEO, Ryu Ogawa, leads the company. Its Series C round on August 18, 2021 raised JPY 790 million from JAFCO Group, Japan Post Capital, SBI Investment and STRIVE, at a valuation of JPY 4,419.614 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in